<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683953</url>
  </required_header>
  <id_info>
    <org_study_id>Guangdong W CH</org_study_id>
    <nct_id>NCT03683953</nct_id>
  </id_info>
  <brief_title>The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells</brief_title>
  <official_title>The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Women and Children Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Women and Children Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect and saftey of intratracheal instillation of mesenchymal stem cells for
      treatment BPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 clinical trial that constitues two points cohorts with 100 participants per
      cohort who will receive instillation dose of mesenchymal stem cells-25 million cells/kg,with
      ventilation after 14 days.And the placebol will be 0.9% sodium choride. The investigator will
      proceed the groups during the same period.

        1. Deographic Data and Baseline charateristics of the studied groups were collected:

           Gestational age (weeks) Birth weight (g) gender Cesarean section delivery Antenatal
           steroids Prolonged rupture of membrane Multiple pregnancies APGAR score at 5 minutes

        2. mesenchymal stem cels dose is 25 million cells/kg

        3. Assessment the incidence of BPD after instillation of Mesenchymal stem cells

        4. the adverse after instillation of Mesenchymal stem cells
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 29, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with BPD after instillation mesenchymal stem cells</measure>
    <time_frame>up to 28 days after birth</time_frame>
    <description>incidence of BPD</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Safety Issues</condition>
  <condition>Effect of Drugs</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% sodium chloride intratracheal instillate on 14 days after birth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mesenchymal stem cells intratracheal instillate on 14 days after birth ,dose is 25 million cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mesenchymal stem cells therapy</intervention_name>
    <description>mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride</intervention_name>
    <description>0.9% sodium chloride in control group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        twenty-eight weeks to thirty-seven weeks prematures who need ventilaton for 14 days after
        birth, and the oxygen concentration is more than 30%

        Exclusion Criteria:

        Preterm infants with major congenital malformations, chromosomal anomalies, inborn errors
        of metabolism and clinical or laboratory evidence of a congenital infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Weeks</minimum_age>
    <maximum_age>37 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Yang, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou, Guangdong,China，511442</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuxiao Ren, MD</last_name>
    <phone>+8613538984634</phone>
    <phone_ext>+86</phone_ext>
    <email>renzhx1990@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jie Yang, PHD</last_name>
    <phone>39151777</phone>
    <phone_ext>020</phone_ext>
    <email>jieyang0830@163.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Mezey É, Nemeth K. Mesenchymal stem cells and infectious diseases: Smarter than drugs. Immunol Lett. 2015 Dec;168(2):208-14. doi: 10.1016/j.imlet.2015.05.020. Epub 2015 Jun 4. Review.</citation>
    <PMID>26051681</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Women and Children Hospital</investigator_affiliation>
    <investigator_full_name>yangjie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>mesenchymal stem cells</keyword>
  <keyword>safety</keyword>
  <keyword>effect</keyword>
  <keyword>BPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchopulmonary Dysplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

